SCNI — Scinai Immunotherapeutics Ltd

Scinai Immunotherapeutics Ltd (SCNI) is a biotechnology company listed on NASDAQ. It is led by Amir Reichman M.B.A., M.Sc., based in Jerusalem BioPark, Jerusalem, Israel, with about 45 employees. Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's syndrome, and toxic epidermal necrolysis. The company also offers contract development and manufacturing organization services, such as analytical method development, process development, and cGMP manufacturing of clinical-stage materials to early-stage biotechnology companies. It has collaboration partnerships with Max Planck Society and University Medical Center Gottingen for the development of NanoAb candidates; and Recipharm Israel Ltd for the development of biologics and small-molecule programs. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is based in Jerusalem, Israel.

Net income was -$3.5M. SCNI currently screens at market cap $1.8M and trailing P/E 0.2.

Use this SCNI page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the SCNI quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the SCNI SEC filings page. Lician reads the product cache first so this HTML stays unique to Scinai Immunotherapeutics Ltd even when a live quote feed is slow.